Combined chemo-radiotherapy in locally advanced nasopharyngeal carcinomas

Table 1 Patients characteristics

Characteristic	Patients
Total	40
Male	33
Female	7
Age, yr, median (range)	60 (24-82)
Stage
IIb	3
III	18
IVa	15
IVb	4
ECOG performance status
0	36
1	4
2	0
Treatment performed induction CT followed by
CCRT1	22
CCRT2	18
Total	40
Induction chemotherapy scheme
PF3	9
TPF4	3
TP5	9
BMC6	1
Total	22
Total radiation dose delivered
70 Gy	36
68 Gy	3
66 Gy	1
Histology squamous cell
G1	1
G2	2
G3	4
Undifferentiated	33

¹Induction chemotherapy followed by concomitant chemo-radiotherapy;

²Concurrent chemoradiotherapy;

³Cisplatin (100 mg/m² every 3 wk) and 5-fluorouracil (5-FU) (1000 mg/m² per day, 4-d continuous infusion every 3 wk);

⁴Docetaxel (75 mg/m² every 3 wk), cisplatin (75 mg/m² every 3 wk) and 5-FU (750 mg/m² per day, 4-d continuous infusion every 3 wk);

⁵Docetaxel (75 mg/m² every 3 wk) and cisplatin (75 mg/m² every 3 wk);

⁶Bleomycin (25 mg/m² on days 1 and 8 of a 21-d cycle), methotrexate (35 mg/m² weekly) and cisplatin (80 mg/m² every 3 wk). ECOG: Eastern Cooperative Oncology Group; CT: Computed tomography.

Table 2 Results n (%)

Treatment performed	Results
ORR	40 (100)
Total (all group)
Induction chemotherapy followed by
CCRT1 group	22 (100)
CCRT2 group	22 (100)
CR rate
Induction chemotherapy followed by	38 (95)
CCRT1 group	21 (95.5)
CCRT2 group	17 (94.4)
3-yr OS
Total (all group)	17 (85)
3-yr DFS
Total (all group)	15 (75)

¹Induction chemotherapy followed by concomitant chemoradiotherapy;

²Concurrent chemoradiotherapy. ORR: Overal response rate; CR: Complete response; OS: Overall survival; DFS: Disease free survival.